12 月 23 日,再鼎医药宣布,NMPA 已批准呫诺美林曲司氯铵胶囊(KarXT,商品名:凯捷乐)的新药上市申请,用于治疗成人精神分裂症。新闻稿指出,这是70 余年来首个获批的具有全新作用机制的精神分裂症疗法,为精神分裂症治疗带来了根本性突破。截图来源:企业官微KarXT 是一种口服 M1/M4 型毒蕈碱乙酰胆碱受体激动剂和毒蕈碱受体拮抗剂的组合。不同于传统靶向多巴胺的抗精神病药物的机制,...
Source Link12 月 23 日,再鼎医药宣布,NMPA 已批准呫诺美林曲司氯铵胶囊(KarXT,商品名:凯捷乐)的新药上市申请,用于治疗成人精神分裂症。新闻稿指出,这是70 余年来首个获批的具有全新作用机制的精神分裂症疗法,为精神分裂症治疗带来了根本性突破。截图来源:企业官微KarXT 是一种口服 M1/M4 型毒蕈碱乙酰胆碱受体激动剂和毒蕈碱受体拮抗剂的组合。不同于传统靶向多巴胺的抗精神病药物的机制,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.